Critical comments for roles of biomarkers in the diagnosis and treatment of cancer
- 1 February 2012
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 38 (1) , 63-67
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerNew England Journal of Medicine, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)British Journal of Cancer, 2007
- The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurementsNature Biotechnology, 2006
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001